In this era of rapidly developing investigational tools and pharmacology, the pathophysiology of precocious puberty is becoming well defined. What was previously thought to be a form of gonadotrophin releasing hormone (GNRH)-dependent central precocious puberty is now classified as GNRH-independent familial testotoxicosis. We present two such cases and review the clinical features, pathophysiology and treatment of testotoxicosis.
Introduction
Sexual precocity is defined as the appearance of physical signs of puberty before 8 years of age in females or 9 years of age in males. The clinical disorders that induce sexual precocity can be classified as gonadotrophin releasing hormone (GNRH) dependent or GNRH independent.' Male sexual precocity first described as a form of central precocious puberty has recently been characterized as a familial intratesticular disorder.2 '3 Sexual development, symmetrical testicular enlargement and accelerated rate of growth are noted by 3 -4 years ofage."3 The pulsatile pattern ofluteinizing hormone (LH) secretion and the immunoreactive and bioactive LH responses to GNRH are similar to these seen in prepubertal children despite markedly elevated concentrations of serum testosterone. We describe two sporadic cases and will review clinical features, diagnosis and treatment of testotoxicosis. The hypothalamic-pituitary gonadotrophin unit operates at a prepubertal level in these patients. 8 The characteristic findings are low basal gonadotrophin levels, absence of sleep-associated LH pulses and lack of a pubertal-type rise in LH concentration after luteinizing hormone releasing factor (LHRF). However, affected adults show a mature LH response to LHRF, whereas FSH is elevated in adults with seminiferous tubule damage, provding evidence that central regulatory pathways are intact. There is lack of excessive testosterone response to administration of human chorionic gonadotrophin (HCG) in boys and absence of testosterone increase after LHRF in adults, despite substantial rises in plasma LH levels. All the above findings are consistent with a primary testicular defect.' Testicular histology shows hyperplasia ofLeydig cells.9 In some affected adults, germ cell degeneration, progressive dysfunction of spermatogenesis and elevated levels of FSH have been observed.9 '0
The pathophysiology of premature Leydig cell activation has still not been clearly elucidated. Salient features of various hypotheses are as follows. Negative LH-HCG activity by bioassay argues against the presence of a circulating gonadotrophin-like factor.3'5 In addition, indirect immunofluorescence studies have been unable to identify a serum immunoglobulin in these patients, comparable to thyroid stimulating hormone immunoglobulin in thyrotoxic patients. Derangement of an intratesticular regulatory mechanism that inhibits Leydig cell function leading to unrestrained activity of these cells has also been proposed.3"''3 Premature Leydig cell activation may also result from local production of a stimulatory factor not detectable in the circulation that stimulates CAMP-dependent kinase to induce testosterone secretion. For example, immunoreactive HCG-like material has been identified in extracts of human testes and other tissues,3'14 and human fetal testes appear able to synthesize HCG. 3"5 Various treatment options have been proposed for testotoxicosis. Initial reports showed that medroxyprogesterone acetate and anti-androgen cypropterone acetate may have some therapeutic benefit.5"0 The mode of action of ketoconazole is inhibition of synthesis of both adrenal and gonadal steroids.'01"67 The disadvantages of ketoconazole are its potential hepatotoxicity and the fact that its use is limited to those patients whose bone age has reached pubertal age.'0 Another approach is blockade of androgen action with spironolactone.4"82' The commonest problem with spironolactone is development of gynaecomastia. Evidence that oestrogens may have an important role in the male pubertal growth spurt22-24 has led to the use of testolactone, a competitive inhibitor of the enzyme aromatase, which converts androgens to oestrogens.25127 There is recent evidence that combination of spironolactone and testolactone may be more beneficial than either alone. 4 In conclusion familial testotoxicosis is a disorder of male isosexual precocity that is inherited as an autosomal dominant condition (although sporadic cases can occur) characterized by gonadotrophin-independent testicular hypersecretion. This condition should be differentiated from gonadotrophin-dependent true precocious puberty as treatment with LHRH analogues may aggravate testotoxicosis. Treatment has not yet been well defined and should be individualized for each case. We believe our two cases either represent sporadic cases or may be a new gene mutation in these two families; long-term follow-up may answer the issue. 
